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Late outcomes of drug eluting and bare 
metal stents in saphenous vein graft 
percutaneous coronary intervention. 
 
Aims: PCI with drug eluting stents (DES) has been shown to reduce restenosis and major 
adverse cardiac event (MACE) rates compared to bare metal stents (BMS) in native coronary 
vessels, although outcomes in saphenous vein graft (SVG) lesions are less clear. We 
retrospectively studied 388 consecutive patients admitted to our centre for SVG PCI to assess 
mortality and MACE outcomes (defined as composite endpoint of all-death, stroke, 
myocardial infarction, stent thrombosis and target lesion (TLR) / vessel (TVR) 
revascularisation) associated with BMS and DES use. 
Methods and results: Two hundred and nineteen (219) patients had BMS and 169 had DES 
(total 388 patients). Mean follow up was 41.9±23.5 months. No significant differences were 
observed in mortality (14.2% vs. 11.8%) or MACE (37.6% vs. 35.8%) between the BMS and 
DES groups at four years follow-up or at other intervening time points studied. Similarly, no 
differences in TVR / TLR rates were observed over a similar time period (19.8% vs. 21.6%). 
Conclusions: We have observed that DES and BMS use in SVG PCI have comparable 
mortality and MACE rates, and that in contrast to PCI in native coronary arteries, DES do not 
reduce revascularisation rates in our study cohort. 
 
